Senores Pharmaceuticals Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Apnar Pharma is a pharmaceutical company primarily engaged in the business of manufacture of generic pharmaceutical formulations, having US FDA, UK-MHRA and Health Canada approved manufacturing facility near Vadodara, Gujarat. Its turnover was Rs 14.21 crore in FY25.

The acquisition will be completed in two tranches, with a first tranche involving the acquisition of 75% stake, expected to be completed in current fiscal by March 2026. The remaining 25% stake is expected to be completed by Q2 of FY 2027.

The company will acquire entire stake at total enterprise value of approximately Rs 91 crore. Of this, around Rs 76 crore represents debt and assumed liabilities related to the manufacturing facility, while the balance of about Rs 15 crore will be paid in cash.

Senores Pharmaceuticals (Senores) is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.

The pharmaceutical company?s consolidated net profit surged 152.18% YoY to Rs 32.28 crore in Q2 FY26. Revenue from operations jumped 56.08% YoY to Rs 153.36 crore in Q2 FY26.

The scrip rose 0.17% to Rs 816.90 on the BSE.

Powered by Capital Market - Live News

Net profit of Senores Pharmaceuticals rose 152.18% to Rs 32.38 crore in the quarter ended September 2025 as against Rs 12.84 crore during the previous quarter ended September 2024. Sales rose 56.08% to Rs 153.36 crore in the quarter ended September 2025 as against Rs 98.26 crore during the previous quarter ended September 2024.

Powered by Capital Market - Live News

Senores Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 6 November 2025.

Powered by Capital Market - Live News

Securities in F&O Ban:

RBL Bank, Angel One and HFCL shares are banned from F&O trading on 19 September 2025.

Stocks to Watch:

Senores Pharmaceuticals announced that it has further made an investment of $1,999,968 (120,480 equity shares at $16.60 each on a rights basis) in its arm, Senores Pharmaceuticals Inc., via a rights issue.

Ramky Infrastructure announced that the Hyderabad Metropolitan Water Supply and Sewerage Board has executed a concessionaire agreement with the company's arm, Mallannasagar Water Supply. The total value of the project is Rs 2,085 crore.

Sterling Holiday Resorts, a subsidiary of Thomas Cook, has launched the 'Sterling Hibis Vellore' resort.

Sai Life Sciences announced that it has successfully opened a dedicated facility for veterinary API production in Bidar, India. With this expansion, the company aims to provide efficient and scalable manufacturing solutions to leading global animal health companies.

Electronics Mart India announced that the company has commenced operations of a new multi-brand store under the brand name Bajaj Electronics in Andhra Pradesh.

PNC Infratech announced that it has received a provisional completion certificate for the project ?Four Laning of LH 5308 from Mathura Bypass?.

Texmaco Rail & Engineering announced that it has received an order worth Rs 87 crore from Ultratech Cement for BCFC wagons along with a brake van.

John Cockerill India announced that it has received a contract from Tata Steel for the Push-Pull Pickling Line and Acid Regeneration Plant.

Century Plyboards (India) announced that it has re-appointed Sajjan Bhajanka as chairman and managing director for five more years, effective 1 April 2026.

Metropolis Healthcare has acquired Ambika Pathology under a business transfer agreement. Post-transfer, the operations of Ambika Pathology are now being carried out under the company.

Indian Hotels Company clarified that the report regarding the sale of New York?s Pierre Hotel is misleading and speculative. The company does not own The Pierre in New York.

Powered by Capital Market - Live News